CA9 and cancer: While the use of CAIX inhibitors as single agents has met with some success, suppressing CAIX function in the context of large-scale unbiased genomic and proteomic approaches has revealed metabolic co-vulnerabilities that, when targeted in combination with CAIX, synergistically enhance ferroptosis of cancer cells.